2016
DOI: 10.1021/acs.orglett.6b01793
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer’s Disease

Abstract: Verubecestat is an inhibitor of β-secretase being evaluated for the treatment of Alzheimer's disease. The first-generation route relies on an amide coupling with a functionalized aniline, the preparation of which introduces synthetic inefficiencies. The second-generation route replaces this with a copper-catalyzed C-N coupling, allowing for more direct access to the target. Other features of the new route include a diastereoselective Mannich-type addition into an Ellman sulfinyl ketimine and a late-stage guani… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
35
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 37 publications
(36 citation statements)
references
References 10 publications
1
35
0
Order By: Relevance
“…1d,e), suggesting that MK-8931 is a potent activator of macrophage phagocytosis of cancer cells. As MK-8931 was originally developed as a BACE1-speci c inhibitor for AD patients 33,41 , we then con rmed that BACE1 was expressed by the iPSC-derived macrophages but not by the iPSCs (Fig. 1f).…”
Section: Identi Cation Of the Bace1 Inhibitor Mk-8931 As A Potent Actmentioning
confidence: 80%
“…1d,e), suggesting that MK-8931 is a potent activator of macrophage phagocytosis of cancer cells. As MK-8931 was originally developed as a BACE1-speci c inhibitor for AD patients 33,41 , we then con rmed that BACE1 was expressed by the iPSC-derived macrophages but not by the iPSCs (Fig. 1f).…”
Section: Identi Cation Of the Bace1 Inhibitor Mk-8931 As A Potent Actmentioning
confidence: 80%
“…Increasing the reaction time from 15 to 20 minutes lead to a slight enhancement of the yield, but any further increase of the reaction time (> 20 min) led to a slight decrease in the reaction yield (Table 1, entries 9-11). Decreasing the iodine loading from 10 mol% to 2 mol% lead to a significant decrease in the conversion of benzaldehyde to the desired sulfinylimine, while increasing the catalyst loading over 10% showed no significant effect on the reaction outcome (Table 1, entries [12][13][14][15]. Addition of anhydrous sodium sulfate (1 equivalent) had no impact on the reaction outcome (Table 1, entry 16).…”
Section: Resultsmentioning
confidence: 99%
“…10 They also find applications in the total synthesis of natural products and biologically active molecules. [11][12][13] Chiral N-sulfinyl imines are the condensation products of carbonyl compounds with commercially available chiral sulfinamides such as p-toluenesulfinamide and tertbutanesulfinamide. However, such condensations typically require the utilization of excess amounts (2-5 equivalents) of metal reagents such as Ti(IV) derivatives and CuSO4 that act as Lewis acids and dehydrating agents at the same time.…”
Section: Introductionmentioning
confidence: 99%
“…In order to process transformations where ar eactive crystallization step is essential, for example,the guanidinylation step toward the synthesis of verubecestat, [28] the reactor set-up was modified. TheBrCN stream with the coupled Br 2 / BrCN generator was introduced into ar eaction vessel containing the substrate solution ( Figure 6), thus mimicking ac ontinuous stirred-tank reactor (CSTR) where slurries can be handled.…”
Section: Angewandte Chemiementioning
confidence: 99%
“…By applying these optimized conditions,as et of 5-membered cyclic guanidines (1a-d)a nd 2-aminobenzoxazoles (2a-g), was synthesized in excellent yields (80-94 %) from the corresponding 1,2-diaminobenzens and 2-aminophenols, respectively (Figure 4). To access the medicinally interesting cyclic 6-membered guanidine moiety, [27,28] 1,3-diamines and 2aminobenzamides were reacted with BrCN to generate cyclic…”
mentioning
confidence: 99%